These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 16257842

  • 1. Hemorheological and hemodynamic changes in predialysis patients after normalization of hemoglobin with epoetin-alpha.
    Furuland H, Linde T, Sandhagen B, Andrén B, Wikström B, Danielson BG.
    Scand J Urol Nephrol; 2005; 39(5):399-404. PubMed ID: 16257842
    [Abstract] [Full Text] [Related]

  • 2. Comparative efficiency and hemorheological consequences of hemotransfusion and epoetin therapy in anemic cancer patients.
    Muravyov AV, Cheporov SV, Kislov NV, Bulaeva SV, Maimistova AA.
    Clin Hemorheol Microcirc; 2010; 44(2):115-23. PubMed ID: 20203366
    [Abstract] [Full Text] [Related]

  • 3. Hemorheological and hemodynamic parameters in patients with essential hypertension and their modification by alpha-1 inhibitor drug treatment.
    Toth K, Kesmarky G, Vekasi J, Nemes J, Czopf L, Kapronczay P, Halmosi R, Papp E, Juricskay I.
    Clin Hemorheol Microcirc; 1999; 21(3-4):209-16. PubMed ID: 10711745
    [Abstract] [Full Text] [Related]

  • 4. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 5. Reduced hemodialysis adequacy after hemoglobin normalization with epoetin.
    Furuland H, Linde T, Wikström B, Danielson BG.
    J Nephrol; 2005 Jun; 18(1):80-5. PubMed ID: 15772927
    [Abstract] [Full Text] [Related]

  • 6. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators.
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [Abstract] [Full Text] [Related]

  • 7. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
    Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY.
    Curr Med Res Opin; 2006 Oct; 22(10):1929-37. PubMed ID: 17022852
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL, Spapen HD, Creteur J, Piagnerelli M, Hubloue I, Diltoer M, Roman A, Stevens E, Vercammen E, Beaver JS.
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [Abstract] [Full Text] [Related]

  • 9. Hyporesponse to Epoetin alfa: patients at risk. Case study of the anemic patient.
    Deziel SM.
    Nephrol Nurs J; 2002 Feb; 29(1):60-3. PubMed ID: 11887489
    [Abstract] [Full Text] [Related]

  • 10. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease.
    Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D.
    J Am Soc Nephrol; 2005 Jul; 16(7):2180-9. PubMed ID: 15901766
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group.
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [Abstract] [Full Text] [Related]

  • 12. Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodialysis patients: results from a Swedish multicentre survey.
    Linde T, Furuland H, Wikström B.
    Scand J Urol Nephrol; 2005 Mar; 39(4):329-33. PubMed ID: 16118109
    [Abstract] [Full Text] [Related]

  • 13. Effect of early correction of anemia on the progression of CKD.
    Rossert J, Levin A, Roger SD, Hörl WH, Fouqueray B, Gassmann-Mayer C, Frei D, McClellan WM.
    Am J Kidney Dis; 2006 May; 47(5):738-50. PubMed ID: 16632012
    [Abstract] [Full Text] [Related]

  • 14. Hemorheological changes in solid tumor patients after treatment with recombinant erythropoetin.
    Muravyov AV, Cheporov SV, Kislov NV, Volkova EL.
    Clin Hemorheol Microcirc; 2009 May; 41(1):39-47. PubMed ID: 19136741
    [Abstract] [Full Text] [Related]

  • 15. Preoperative epoetin alfa in colorectal surgery: a randomized, controlled study.
    Christodoulakis M, Tsiftsis DD, Hellenic Surgical Oncology Perioperative EPO Study Group.
    Ann Surg Oncol; 2005 Sep; 12(9):718-25. PubMed ID: 16052276
    [Abstract] [Full Text] [Related]

  • 16. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study.
    Milutinović S, Plavljanić E, Trkulja V.
    Fundam Clin Pharmacol; 2006 Oct; 20(5):493-502. PubMed ID: 16968421
    [Abstract] [Full Text] [Related]

  • 17. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.
    Schroth M, Plank C, Meissner U, Eberle KP, Weyand M, Cesnjevar R, Dötsch J, Rascher W.
    Pediatrics; 2006 Jul; 118(1):e76-84. PubMed ID: 16751617
    [Abstract] [Full Text] [Related]

  • 18. Epoetin alfa's effect on left ventricular hypertrophy and subsequent mortality.
    Jones M, Schenkel B, Just J.
    Int J Cardiol; 2005 Apr 20; 100(2):253-65. PubMed ID: 15823633
    [Abstract] [Full Text] [Related]

  • 19. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
    Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN.
    J Clin Oncol; 2007 Mar 20; 25(9):1027-32. PubMed ID: 17312332
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr 20; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.